Abstract: Balhimycin, where appropriate in combination with one or more of its derivatives, is suitable for promoting production in monogastric or polygastric animals.

Abstract: Cyclic analogs of PTH and PTHrP wherein a disulfide or amide bond links the side chains of residues A.sub.13 and A.sub.17, A.sub.26 and A.sub.30, or A.sub.13 and A.sub.17 and A.sub.26 and A.sub.30.

Abstract: A method of fabricating nanoscale structural materials via the spontaneous organization of self-assembling proteins and the self-assembling proteins themselves. In a preferred embodiment of the invention, the self-assembling proteins included at least one occurrence of the following recognition sequence: ##STR1## wherein Xaa is a charged residue selected from the group consisting of Glu, Lys, Arg and Asp, and the method comprises admixing proteins which include species of the aforementioned recognition sequence which are prone to dimerization, whereby the admixed proteins are caused to spontaneously organize into nanoscale structural materials via their respective recognition sequences.

Abstract: The present invention relates to a method of augmenting soft tissue in a mammal which includes injecting keratin into the soft tissue. The method of the present invention may be used to treat incontinence and vesicoureteral reflux.

Abstract: A process of synthesizing a peptide using an alkylene oxide as an acid scavenger is provided. A process of the present invention can be used in a solid phase or solution phase synthetic process where peptide synthesis occurs by the sequential addition of N-.alpha.-amino-Boc-protected residues followed by acid deprotection of that N-.alpha.-amino protecting group and scavenging of the acid.

Abstract: This invention relates to Aureobasidins useful as an antifungal agent having broader spectrum. The compound according to this invention includes a cyclic depsipeptide consisting of one hydroxy acid residue having A.sup.1, 3 amino acid residues having C.sup.1, F.sup.1 and H.sup.1, respectively, 4 N-methylamino acid residues having B.sup.1, D.sup.1, G.sup.1 and I.sup.1, respectively, and 1 cyclic amino acid residue having E.sup.1. The typical compound includes one wherein A.sup.1 is CH.sub.3 CH.sub.2 CH(CH.sub.3)--, B.sup.1 is (CH.sub.3).sub.2 CH--, C.sup.1 is benzyl, cyclohexylmethyl, p-fluorobenzyl, benzyloxymethyl, benzyloxybenzyl, methoxybenzyl, cyclohexylmethyloxybenzyl or the like, D.sup.1 is methyl, benzyl, hydroxymethyl or the like, E.sup.1 is --(CH.sub.2).sub.3 --, F.sup.1 is CH.sub.3 CH.sub.2 CH(CH.sub.3)--, G.sup.1 is (CH.sub.3).sub.2 CH--, H.sup.1 is (CH.sub.3).sub.2 CHCH.sub.2 -- and I.sup.1 is (CH.sub.3).sub.2 C(OH)--.

Abstract: Vasopressin analogues of formula (I) ##STR1## wherein X is (S)-2-amino-2-methyl-butanoic acid (CaMeAbu) or Valine (Val), Y is Thienylalanine (Thi) or Methionine (Met), Z is D-Phenylalanine (D-Phe) or D-Thienylalanine (Thi) or D-Tyrosine (D-Tyr), are disclosed. Pharmaceutical preparations comprising a vasopressin analogue of the invention as active ingredient are disclosed and exemplified by oral preparations, nasal preparations, and intravenous preparations. The vasopressin analogues of the invention are intended for use as a medicament, specially an antidiuretic agent. The antidiuretic agent is preferably used for the treatment of diabetes insipidus or enuresis.

Abstract: A composition containing taxol for the ex vivo preservation or perfusion of organs for implantation in a subject requiring such implantation, or for cardioplegia, is disclosed.

Abstract: A process for preparing a polypeptide compound having antimicrobial activities of the following general formula: ##STR1## wherein R.sup.1 is hydrogenR.sup.2 is acyl group,R.sup.3 is hydroxy or acyloxy,R.sup.4 is hydroxy or hydroxysulfonyloxy,R.sup.5 is hydrogen or lower alkyl which may have one or more suitable substituent(s), andR.sup.6 is hydrogen, hydroxy or acyl (lower) alkylthio anda pharmaceutically acceptable salt thereof.

Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Abstract: Liquid pharmaceuticals for subcutaneous (sc) or intramuscular (im) administration containing a polypeptide and at least one amino acid, a process for the preparation of such a pharmaceutical and the use of an amino acid, which is suitable for sc or im administration, in a solution of a polypeptide are described.

Abstract: Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Abstract: In order to remove tumor necrosis factor .alpha. (TNF.alpha.) or/and bacterial lipopolysaccharides (LPS, endotoxin) extracorporeally from whole blood or/and blood plasma in an extracorporeal perfusion system, the blood or plasma is passed over a cation exchanger and an anion exchanger material. A device according to the invention for the extracorporeal treatment of patient's blood or plasma therefore contains a cation exchanger material and an anion exchanger material wherein these materials are contained in at least one compartment of an extracorporeal perfusion system.

Abstract: Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Abstract: The invention comprises purified trypsin inhibitors extracted from the seeds of Pentaclethra macroloba. The crude extract was found to comprise two molecular weight ranges of 38-35 and 6-9 kDa which contain the active compounds. Within each molecular weight range, the trypsin inhibitors were found to exist in two isoforms. The lower molecular weight inhibitor exhibits surprising stability and activity after heating in aqueous solution at approximately 100.degree. C. for 30 minutes.

Abstract: Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Abstract: LHRH analogs and congeners with high water solubility have been synthesized. These new analogs had 0%-100% antiovulatory activity at a 0.5 .mu.g dosage and 0%-80% at 0.25 .mu.g. The ED.sub.50 for histamine release was 30.5 .mu.g/ml->300 .mu.g/ml.

Abstract: Described are peptides and peptide mimetics that bind to and the IL-receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Abstract: The present invention contemplates a composition and method for treating septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a therapeutically effective amount of a bacterial lipopolysaccharide binding peptide derived from CAP37 protein. In a preferred version, the composition and method of use may comprise a peptide comprising amino acids 20-44 of CAP37 or a subunit thereof.

Abstract: The present invention relates to a method of imparting pathogen resistance to plants. This involves applying a hypersensitive response elicitor polypeptide or protein in a non-infectious form to a plant under conditions where the polypeptide or protein contacts cells of the plant. The present invention is also directed to a pathogen resistant plant and a composition for imparting pathogen resistance to plants.